UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Evaluation Study
  • Authors:
    Turner-Stokes T, Lu TY, Ehrenstein MR, Giles I, Rahman A, Isenberg DA
  • Publication date:
    08/2011
  • Pagination:
    1401, 1408
  • Journal:
    Rheumatology (Oxford)
  • Volume:
    50
  • Issue:
    8
  • Status:
    Published
  • Country:
    England
  • PII:
    ker018
  • Language:
    eng
  • Keywords:
    Adult, Antibodies, Monoclonal, B-Lymphocytes, Cyclophosphamide, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Infliximab, Leukocyte Reduction Procedures, Lupus Erythematosus, Systemic, Prednisolone, Remission Induction, Treatment Outcome
Abstract
OBJECTIVE: Since 2000, we have given B-cell depletion therapy (BCDT) with rituximab to 76 patients with active SLE refractory to standard immunosuppression. Twenty-four of these patients have now received repeated cycles of BCDT. The aims of the study were to: (i) assess the efficacy and safety of repeated cycles of BCDT in treating refractory SLE; and (ii) assess whether retreatment produced a more sustained clinical response. METHODS: BCDT was administered using CYC 750 mg, methylprednisolone 125-250 mg and rituximab 1 g given intravenously on two occasions, 2 weeks apart. Patients were reviewed at 1-2 monthly intervals and disease activity assessed using the BILAG activity index and serological markers. Clinical response was categorized as complete or partial remission, or no response, based on the change in BILAG scores. RESULTS: Eighteen patients had sufficient data for detailed analysis. All were female; mean age 29.9 years; mean duration of follow-up 58.7 months. Two patients died during follow-up and there were two infusion reactions. Disease activity was significantly reduced after both cycles of BCDT at 6 months. More patients achieved disease remission after the second cycle (82 vs 61% first cycle), which was maintained in 65% at 12 months (vs 39% first cycle). The time to disease flare was significantly longer after the second cycle (P < 0.001) and 33% of our patients have still not flared to date following retreatment (mean follow-up 24.5 months). CONCLUSION: Repeated cycles of BCDT with rituximab are effective in treating refractory SLE and has a favourable safety profile. Retreatment may produce a more sustained clinical response.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Inflammation
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by